UBS Group’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-21,311
| Closed | -$392K | – | 8600 |
|
|
2020
Q4 | $392K | Sell |
21,311
-2,715
| -11% | -$49.9K | ﹤0.01% | 3859 |
|
|
2020
Q3 | $441K | Buy |
24,026
+16,859
| +235% | +$309K | ﹤0.01% | 3519 |
|
|
2020
Q2 | $107K | Sell |
7,167
-1,493
| -17% | -$22.3K | ﹤0.01% | 4431 |
|
|
2020
Q1 | $137K | Sell |
8,660
-6,526
| -43% | -$103K | ﹤0.01% | 4178 |
|
|
2019
Q4 | $247K | Buy |
15,186
+5,024
| +49% | +$81.7K | ﹤0.01% | 4460 |
|
|
2019
Q3 | $151K | Buy |
10,162
+6,370
| +168% | +$94.7K | ﹤0.01% | 4566 |
|
|
2019
Q2 | $63K | Buy |
3,792
+3,160
| +500% | +$52.5K | ﹤0.01% | 4875 |
|
|
2019
Q1 | $11K | Sell |
632
-3,654
| -85% | -$63.6K | ﹤0.01% | 5945 |
|
|
2018
Q4 | $76K | Buy |
4,286
+1,361
| +47% | +$24.1K | ﹤0.01% | 4892 |
|
|
2018
Q3 | $53K | Buy |
2,925
+879
| +43% | +$15.9K | ﹤0.01% | 5233 |
|
|
2018
Q2 | $40K | Buy |
+2,046
| New | +$40K | ﹤0.01% | 5273 |
|
|
2017
Q4 | – | Sell |
-1,507
| Closed | -$16K | – | 7074 |
|
|
2017
Q3 | $16K | Buy |
1,507
+1,376
| +1,050% | +$14.6K | ﹤0.01% | 5715 |
|
|
2017
Q2 | $1K | Sell |
131
-1,208
| -90% | -$9.22K | ﹤0.01% | 6599 |
|
|
2017
Q1 | $16K | Sell |
1,339
-2,145
| -62% | -$25.6K | ﹤0.01% | 5404 |
|
|
2016
Q4 | $46K | Buy |
3,484
+140
| +4% | +$1.85K | ﹤0.01% | 4977 |
|
|
2016
Q3 | $48K | Buy |
+3,344
| New | +$48K | ﹤0.01% | 4694 |
|
|
2015
Q4 | – | Sell |
-1,502
| Closed | -$25K | – | 7079 |
|
|
2015
Q3 | $25K | Sell |
1,502
-2,701
| -64% | -$45K | ﹤0.01% | 5271 |
|
|
2015
Q2 | $158K | Sell |
4,203
-12,497
| -75% | -$470K | ﹤0.01% | 4028 |
|
|
2015
Q1 | $525K | Buy |
16,700
+14,037
| +527% | +$441K | ﹤0.01% | 3197 |
|
|
2014
Q4 | $34K | Buy |
+2,663
| New | +$34K | ﹤0.01% | 5060 |
|